Straits Times Index
3,293.64 +0.95 (+0.03%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,207.13 +444.10 (+2.50%) FTSE 100
8,154.40 +33.16 (+0.41%) Bitcoin USD
57,869.06 +900.17 (+1.58%) CMC Crypto 200
1,268.43 -2.32 (-0.18%)
Swedish Orphan Biovitrum AB (SOBIS.XD)
| Previous close | 287.00 |
| Open | 284.20 |
| Bid | 281.60 x 0 |
| Ask | 282.00 x 0 |
| Day's range | 281.20 - 287.00 |
| 52-week range | 281.20 - 287.00 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
- PR Newswire
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
- PR Newswire
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
